drugset / Trial / NCT05309564
Muscle Weakness Duration After Single Botulinum Toxin Injection in Masseter
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aimed to evaluate the duration of a reduced maximal voluntary bite force after a botulinum toxin intervention. Methods: In an intervention group, 25 units of Xeomin® (Merz Pharma GmbH \& Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A were injected into the masseter muscles bilaterally (to a total of 50 units).
Timeline
- Start
- 2020-03-01
- Primary completion
- 2022-01-10
- Completion
- 2022-03-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 50 iu | Intramuscular |